299 related articles for article (PubMed ID: 21965770)
1. Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus.
Paule B; Brion N
Anticancer Res; 2011 Oct; 31(10):3507-10. PubMed ID: 21965770
[TBL] [Abstract][Full Text] [Related]
2. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
Blesius A; Beuselinck B; Chevreau C; Ravaud A; Rolland F; Oudard S; Escudier B
Clin Genitourin Cancer; 2013 Jun; 11(2):128-33. PubMed ID: 23332872
[TBL] [Abstract][Full Text] [Related]
3. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ
Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790
[TBL] [Abstract][Full Text] [Related]
5. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E
Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560
[TBL] [Abstract][Full Text] [Related]
6. More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus.
Oudard S
Anticancer Res; 2010 Dec; 30(12):5223-5. PubMed ID: 21187517
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
8. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
Di Lorenzo G; Casciano R; Malangone E; Buonerba C; Sherman S; Willet J; Wang X; Liu Z; De Placido S
Expert Opin Pharmacother; 2011 Jul; 12(10):1491-7. PubMed ID: 21599551
[TBL] [Abstract][Full Text] [Related]
9. Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
Beck J; Bellmunt J; Escudier B
Med Oncol; 2011 Dec; 28(4):1379-83. PubMed ID: 20593250
[TBL] [Abstract][Full Text] [Related]
10. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
Chen CC; Hess GP; Liu Z; Gesme DH; Agarwala SS; Garay CC; Hill JW; Guo A
Clin Genitourin Cancer; 2012 Dec; 10(4):256-61. PubMed ID: 22682982
[TBL] [Abstract][Full Text] [Related]
11. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
Busch J; Seidel C; Kempkensteffen C; Johannsen M; Wolff I; Hinz S; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2011 Dec; 60(6):1163-70. PubMed ID: 21802830
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.
Buchler T; Bortlicek Z; Poprach A; Kubackova K; Kiss I; Zemanova M; Fiala O; Dusek L; Vyzula R; Melichar B;
Urol Oncol; 2014 Jul; 32(5):569-75. PubMed ID: 24629497
[TBL] [Abstract][Full Text] [Related]
14. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma.
Larkin J; Esser N; Calvo E; Tsuchihashi Z; Fiedler U; Graeser R; Kim D
Anticancer Res; 2012 Jul; 32(7):2399-406. PubMed ID: 22753696
[TBL] [Abstract][Full Text] [Related]
16. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Leung HW; Chan AL
Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
18. Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib.
Molina AM; Ginsberg MS; Motzer RJ
Med Oncol; 2011 Dec; 28(4):1527-9. PubMed ID: 20697842
[TBL] [Abstract][Full Text] [Related]
19. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
20. "Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.
Harrison MR; George DJ; Walker MS; Chen C; Korytowsky B; Kirkendall DT; Stepanski EJ; Abernethy AP
Clin Genitourin Cancer; 2013 Dec; 11(4):441-50. PubMed ID: 23856102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
